Skip to content
ModernDocHealth
Contact

Skip to section

Pulmonology

What the Latest Research Reveals

Data last updated: 30 studies cited

How this page is produced

Generated by the ModernDoc Research Monitor from peer-reviewed literature. Every statistic is automatically checked against its cited source and screened for retractions before it is published. This page is AI-generated and has not yet been reviewed by a clinician — it is not medical advice. Read how we build and check these pages.

24-38%
Persistent DLCO Impairment at 12 Months
Among hospitalized COVID-19 survivors
Source: Huang L et al.. Lancet (2021). 10.1016/S0140-6736(21)01755-4 | n=1276

KEY FINDINGS

DLCO Impairment at 12 Months
24-38%
95% CI: 95% CI: 18-45%
Source [7]
Persistent CT Abnormalities at 12 Months
22-32%
95% CI: 95% CI: 18-38%
Source [10]
Post-COVID Fibrotic Changes (Hospitalized)
11-20%
95% CI: 95% CI: 8-25%
Source [7]
Reduced 6MWD at 12 Months
15-25%
95% CI: 95% CI: 10-32%
Source [7]

THE TIMELINE

Acute Phase

0-4 weeks

Extensive GGO and consolidation on CT in 75-95% of hospitalized patients; ARDS in 15-30%

Key Event
Peak ARDS risk and diffuse alveolar damage

DLCO Impairment at 6 Months Post-ARDS

Source: Burnham EL et al., Crit Care Med 2013; COVID studies meta-analysis

Cumulative Pulmonary Risk with Reinfection

1 infection+Reference
2 infections+94% higher
3+ infections+~150% higher

“Reinfection associated with cumulative risk increase for respiratory conditions. Each infection adds to cumulative lung injury.”

THE HOPEFUL HORIZON

  • Complete pulmonary recovery occurs in 60-70% of hospitalized COVID-19 survivors[7]
  • Pulmonary rehabilitation improves 6MWD by 65m (95% CI: 40-90m) in 6-week programs[16]
  • Many 'fibrotic-like changes' resolve over 12-24 months - not all are permanent[23]
  • Improvement can continue even at 24 months in 35% of those with abnormalities at 12 months

SOURCES

  1. [1]Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology. 2021;27(4):328-337. DOI (opens in new tab)
  2. [2]Suh YJ, Hong H, Ohana M, et al. Pulmonary embolism and deep vein thrombosis in COVID-19: A systematic review and meta-analysis. Radiology. 2021;298(2):E70-E80. DOI (opens in new tab)
  3. [3]Jenner WJ, Gober IM, Engleton E, et al. Pulmonary embolism and COVID-19: Meta-analysis of risk assessment tools. European Respiratory Journal. 2021;58(2):2100169. DOI (opens in new tab)
  4. [4]Fernandez-de-las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. European Journal of Internal Medicine. 2021;92:55-70. DOI (opens in new tab)
  5. [5]Fabbri L, Moss S, Khan FA, et al. Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis. Thorax. 2023;78(2):191-201. DOI (opens in new tab)

See a problem with the Pulmonology research summary?

Send a source correction or freshness concern. We cannot provide personal medical advice through this site.

Report a correction

SHARE THIS INFORMATION

Share with someone who needs to know

Back to DashboardReport an Issue

Data last updated:

Medical review: AI-generated — pending clinician review

Sources cited: 30 peer-reviewed sources

Claim verification: 0/0 verified (NaN%)

About DOIs

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for medical decisions. Data is sourced from peer-reviewed publications and may be updated as new research emerges.